An international randomized phase III study of first-line erlotinib followed by second-line cisplatin + gemcitabine versus first-line cisplatin + gemcitabine followed by second-line erlotinib in advanced non small cell lung cancer

Trial Profile

An international randomized phase III study of first-line erlotinib followed by second-line cisplatin + gemcitabine versus first-line cisplatin + gemcitabine followed by second-line erlotinib in advanced non small cell lung cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms TORCH
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 May 2013 Results of an economic analysis in Canada presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 09 Jul 2012 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top